Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;391(7):705-717.
doi: 10.1007/s00210-018-1497-1. Epub 2018 Apr 18.

Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats

Rania G Abdel-Latif  1 , Gehan H Heeba  2 , Ashraf Taye  1 , Mohamed M A Khalifa  1
Affiliations

Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats

Rania G Abdel-Latif et al. Naunyn Schmiedebergs Arch Pharmacol. 2018 Jul.

Abstract

Type 2 diabetes mellitus (T2DM) is a major risk factor for ischemic stroke accompanied by vascular dysfunction and poor cerebrovascular outcome. Lixisenatide is a glucagon like peptide-1 (GLP-1) analog that is recently used for T2DM treatment with established neuroprotective properties. This study investigated and compared the neuroprotective effect of lixisenatide against glimepiride on diabetic rats subjected to global cerebral ischemia/reperfusion (I/R) injury. T2DM-induced adult male Wistar rats were administered lixisenatide or glimepiride prior to induction of global cerebral I/R-induced injury. Results showed a disturbance in oxidative stress parameters (catalase, reduced glutathione, and malondialdehyde) along with increasing in caspase-3 and tumor necrosis factor-alpha protein expressions in ischemic diabetic brain tissues. An upregulation of protein level of inducible nitric oxide (iNOS) synthase and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit, NOX2 gene expression associated with significant suppression of endothelial nitric oxide synthase (eNOS) protein expression are recorded in carotid arteries of diabetic I/R-injured rats. Apart from ameliorating glucose intolerance and insulin resistance, lixisenatide was found to be superior to glimepiride as protective treatment in terms of enhancing behavioral/neurological functions and suppressing cerebral oxidative stress, inflammation, and apoptosis in cerebral I/R-injured diabetic rats. Unlike glimepiride, lixisenatide relieved carotid endothelial dysfunction by increasing eNOS expression. It also dampened vascular nitrosative/oxidative stress via suppression of iNOS and NADPH oxidase expressions. This study supposed that lixisenatide represents a more suitable anti-diabetic therapy for patients who are at risk of ischemic stroke, and even so, the mechanisms of lixisenatide-mediated vascular protection warrant further experimental and clinical investigations.

Keywords: Cerebral ischemia/reperfusion; GLP-1; Glimepiride; Lixisenatide; Type 2 diabetes mellitus; Vascular injury.

PubMed Disclaimer

References

    1. Stroke. 2004 Jun;35(6):1449-53 - PubMed
    1. Cardiovasc Diabetol. 2014 Apr 02;13:69 - PubMed
    1. Diab Vasc Dis Res. 2016 Sep;13(5):367-72 - PubMed
    1. Curr Med Res Opin. 2017 Oct;33(10 ):1861-1868 - PubMed
    1. Arzneimittelforschung. 2001;51(8):628-32 - PubMed

MeSH terms

LinkOut - more resources